Literature DB >> 12564849

Hyperamylasaemia and multiple myeloma.

Colleen M Ross1, Manjit S Devgun, Ian R Gunn.   

Abstract

This case report describes a 42-year-old Caucasian woman who presented with persistent hyperamylasaemia and no evidence of pancreatic pathology. Further investigations resulted in a diagnosis of light-chain multiple myeloma. Amylase production by epithelial tumours has been well documented but the association with multiple myeloma has only been described in a small number of cases. The link does not appear to be immunoglobulin class-specific but the association with Bence Jones myeloma is unusual. The common features in this group of patients have been extensive extramedullary spread with a high tumour mass and a poor prognosis. This case was similar in that the patient showed very rapid disease activity developing extensive metastatic lesions and treatment ultimately proved unsuccessful. The amylase concentrations have been shown to decrease in response to treatment and increase at times of relapse and it has been proposed that it may be useful as a tumour marker in these patients. This case study adds to the pool of patents with this unusual association.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12564849     DOI: 10.1177/000456320203900615

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  3 in total

1.  Hyperamylasaemia: not the usual suspects.

Authors:  Rajeev Srivastava; Callum Fraser; Douglas Gentleman; Lynne A Jamieson; Michael J Murphy
Journal:  BMJ       Date:  2005-10-15

2.  A case report of a salivary amylase secreting plasmacytoma in a patient with multiple myeloma.

Authors:  Serena L Harborne; Rachael Curley; David W Bullimore; Dominic Chan-Lam; Jean-Pierre Ng; Philip T McAndrew
Journal:  BMJ Case Rep       Date:  2009-05-17

3.  Hyperamylasaemia: pathognomonic to pancreatitis?

Authors:  Sam Burden; Anna Sau Kuk Poon; Kausar Masood; Mohamed Didi
Journal:  BMJ Case Rep       Date:  2013-10-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.